Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Facing skeptical FDA, company in partnering talks as more Phase III data with anti-inflammatory drug prove positive.
You may also be interested in...
NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
French firm plans to build U.S. sales force to market osteoarthritis drug and complementary products it will acquire or license.
NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
French firm plans to build U.S. sales force to market osteoarthritis drug and complementary products it will acquire or license.
NicOx Blood Pressure Data Positive, But Is it Enough?
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod